バイオシミラーホルモンの世界市場レポート 2024年

バイオシミラーホルモンの市場規模は、今後数年間で急激に成長すると予想されます。 2028年には24.0%の年間複合成長率（CAGR）で117億7,000万米ドルに成長すると予想されます。予測期間の予想される成長は、いくつかの重要な要因により予想されます。これらには、治療対象のホルモンの拡大、患者の間でのバイオシミラーホルモンの受け入れの増加、生産効率を高める製造技術の進歩、政府の支援、その有効性を裏付ける豊富な臨床試験データの増加、医療サービスへのより幅広いアクセスが含まれます。

バイオシミラーホルモン市場は、成長ホルモンと代謝ホルモンの欠乏症の蔓延により成長が見られます。 1月のBritish Medical Journalの報告によると、ホルモン関連疾患の治療法の進歩により、バイオシミラーホルモンの需要が増加しています。これは、小児における成長ホルモン欠乏症（GHD）の世界の推定罹患率が3,500人に1人から1万人に1人の範囲であると推定されていることによって促進されています。 さらに、米国では約6,000人の成人が成長ホルモン欠乏症と診断されると予測されており、ホルモン欠乏症に対処する必要性が高まっており、それがバイオシミラーホルモンの市場成長を促進していることが強調されています。

糖尿病の有病率の拡大は、バイオシミラーホルモン市場の成長の重要な推進力になると予想されます。糖尿病は、食物からのエネルギー変換に影響を与える持続的な症状であり、糖尿病管理の安全で効果的な代替品として、バイオシミラーホルモン、特にインスリンに大きな市場機会をもたらします。バイオシミラー成長ホルモンは、1型と2型糖尿病の成人の血糖コントロールを強化することにより、糖尿病の管理にも役割を果たします。国際糖尿病連盟の2021年 7月の報告書は、世界の糖尿病人口が2030年までに6億4,300万人、2045年までに7億8,300万人に急増すると予測しています。これに対し、2021年の糖尿病患者数は約5億3,700万人です。この糖尿病の有病率の拡大は、バイオシミラーホルモン市場の活性化を促進することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のバイオシミラーホルモン市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のバイオシミラーホルモンの市場規模実績と成長、2018～2023年
• 世界のバイオシミラーホルモン市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のバイオシミラーホルモン市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• テリパラチドバイオシミラー
• フォリトロピンアルファバイオシミラー
• インスリンバイオシミラー
• ソマトロピンバイオシミラー
• その他
• 世界のバイオシミラーホルモン市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 調査とバイオテクノロジー
• 診断
• 生体触媒
• 治療
• その他
• 世界のバイオシミラーホルモン市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院と小売薬局
• オンライン薬局/薬局
• 専門クリニック

第7章 地域と国の分析

• 世界のバイオシミラーホルモン市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のバイオシミラーホルモン市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラーホルモン市場の競合情勢
• バイオシミラーホルモン市場の企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • Gedeon Richter Plc.
  • Intas Pharmaceuticals Ltd.
  • Biocon Limited
  • Mylan

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

Biosimilar hormones refer to hormone products that mirror the chemical structure of the hormones naturally produced by the human body. In many cases, these hormones in bioidentical drugs closely resemble those utilized in traditional hormone therapy. They are employed to address imbalances or deficiencies in hormone levels within individuals.

The primary categories of biosimilar hormones encompass teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars, among others. Teriparatide, for instance, is a recombinant form of parathyroid hormone (PTH). It functions similarly to a component of human PTH and, when administered regularly, stimulates osteoblasts more than osteoclasts, thereby enhancing bone mass. These hormones find diverse applications in research and biotechnology, diagnostics, biocatalysts, therapeutics, and various other fields. They are made available through multiple distribution channels, including hospital and retail pharmacies, online pharmacies or e-pharmacy platforms, as well as specialty clinics, catering to different healthcare needs and preferences.

The biosimilar hormones market research report is one of a series of new reports from The Business Research Company that provides biosimilar hormones market statistics, including biosimilar hormones industry global market size, regional shares, competitors with a biosimilar hormones market share, detailed biosimilar hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar hormones industry. The biosimilar hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar hormones market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 27.5%. The growth observed in the historical period can be attributed to several factors. These include the escalating prevalence of chronic diseases requiring hormone treatments, a growing aging population necessitating hormone management, heightened awareness regarding the benefits of biosimilar hormones, and expanded accessibility to healthcare services facilitating their use among a wider demographic. These factors collectively contributed to the growth and adoption of biosimilar hormones during this period.

The biosimilar hormones market size is expected to see exponentially grown in the next few years. It will grow to $11.77 billion in 2028 at a compound annual growth rate (CAGR) of 24.0%. Anticipated growth in the forecast period is expected due to several key factors. These include the expansion of hormone targets for treatment, increasing acceptance of biosimilar hormones among patients, advancements in manufacturing techniques enhancing production efficiency, governmental support, a wealth of growing clinical trial data supporting their efficacy, and wider accessibility to healthcare services.

The biosimilar hormones market is seeing growth due to the prevalence of deficiencies in growth and metabolic hormones. Advancements in treatments for hormone-related conditions have led to increased demand for biosimilar hormones, fueled by the estimated global prevalence of growth hormone deficiency (GHD) in children ranging from 1 in 3500 to 1 in 10000, as reported by the British Medical Journal in January 2022. Additionally, approximately 6,000 adults in the USA are projected to be diagnosed with growth hormone deficiency, underlining the escalating need to address hormonal deficiencies, which drives the market growth for biosimilar hormones.

The expanding prevalence of diabetes is anticipated to be a significant driver of growth in the biosimilar hormones market. Diabetes, a persistent condition affecting energy conversion from food, presents a substantial market opportunity for biosimilar hormones, particularly insulin, as safe and effective alternatives for diabetes management. Biosimilar growth hormone also plays a role in managing diabetes by enhancing blood sugar control in adults with type 1 and type 2 diabetes. The International Diabetes Federation's July 2021 report projects a surge in the global diabetic population to 643 million by 2030 and 783 million by 2045, compared to approximately 537 million adults living with diabetes in 2021. This escalating prevalence of diabetes is set to propel the biosimilar hormones market's growth in the foreseeable future.

Key players in the biosimilar hormones market are actively implementing strategic initiatives, such as expanding into untapped regions through new product launches, aiming to increase accessibility and capture wider market segments. Notably, Alvotech Holdings S.A., in February 2022, announced a strategic partnership with Fuji Pharma Co. Ltd., intending to develop biosimilar drug candidates specifically targeted for the Japanese market. This alliance represents a focused effort to create and market biosimilar medicines in Japan, demonstrating a strategic move to enhance market presence and generate higher revenues.

Major companies operating in the biosimilar hormones sector are innovating with new product launches to augment their market profitability. Novo Nordisk's FDA approval in April 2023 for Sogroya (somapacitan-beco) injection marks a significant milestone. Sogroya, designed as a once-weekly growth hormone therapy for children and adults, gained a new indication for treating children aged 2.5 years and older with growth failure due to insufficient endogenous growth hormone secretion. Supported by findings from the phase 3 REAL4 trial, this approval validates Sogroya's efficacy in addressing growth hormone deficiency in pediatric patients, representing a strategic move to strengthen their market position and profitability.

Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd., Merck & Co., Biogen Inc., Boehringer Ingelheim, Coherus BioSciences Inc., Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

North America was the largest region in the biosimilar hormones market in 2023. The regions covered in the biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar hormones market consists of sales of estrace, estradil, and estring. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilar Hormones Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar hormones market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar hormones? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilar hormones market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Teriparatide Biosimilars; Follitropin Alfa Biosimilars; Insulin Biosimilars; Somatropin Biosimilars; Other Types
• 2) By Application: Research & Biotechnology; Diagnostics; Biocatalysts; Therapeutics; Other Applications
• 3) By Distribution Channel: Hospital And Retail Pharmacy; Online Pharmacy/pharmacy; Specialty Clinics
• Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Gedeon Richter Plc.; Intas Pharmaceuticals Ltd.; Biocon Limited; Mylan
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilar Hormones Market Characteristics

3. Biosimilar Hormones Market Trends And Strategies

4. Biosimilar Hormones Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Biosimilar Hormones Market Size and Growth

• 5.1. Global Biosimilar Hormones Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Biosimilar Hormones Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Biosimilar Hormones Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biosimilar Hormones Market Segmentation

• 6.1. Global Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Teriparatide Biosimilars
• Follitropin Alfa Biosimilars
• Insulin Biosimilars
• Somatropin Biosimilars
• Other Types
• 6.2. Global Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Research & Biotechnology
• Diagnostics
• Biocatalysts
• Therapeutics
• Other Applications
• 6.3. Global Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital And Retail Pharmacy
• Online Pharmacy/pharmacy
• Specialty Clinics

7. Biosimilar Hormones Market Regional And Country Analysis

• 7.1. Global Biosimilar Hormones Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Biosimilar Hormones Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biosimilar Hormones Market

• 8.1. Asia-Pacific Biosimilar Hormones Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biosimilar Hormones Market

• 9.1. China Biosimilar Hormones Market Overview
• 9.2. China Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biosimilar Hormones Market

• 10.1. India Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biosimilar Hormones Market

• 11.1. Japan Biosimilar Hormones Market Overview
• 11.2. Japan Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biosimilar Hormones Market

• 12.1. Australia Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biosimilar Hormones Market

• 13.1. Indonesia Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biosimilar Hormones Market

• 14.1. South Korea Biosimilar Hormones Market Overview
• 14.2. South Korea Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biosimilar Hormones Market

• 15.1. Western Europe Biosimilar Hormones Market Overview
• 15.2. Western Europe Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biosimilar Hormones Market

• 16.1. UK Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biosimilar Hormones Market

• 17.1. Germany Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biosimilar Hormones Market

• 18.1. France Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biosimilar Hormones Market

• 19.1. Italy Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biosimilar Hormones Market

• 20.1. Spain Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biosimilar Hormones Market

• 21.1. Eastern Europe Biosimilar Hormones Market Overview
• 21.2. Eastern Europe Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biosimilar Hormones Market

• 22.1. Russia Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biosimilar Hormones Market

• 23.1. North America Biosimilar Hormones Market Overview
• 23.2. North America Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biosimilar Hormones Market

• 24.1. USA Biosimilar Hormones Market Overview
• 24.2. USA Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biosimilar Hormones Market

• 25.1. Canada Biosimilar Hormones Market Overview
• 25.2. Canada Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biosimilar Hormones Market

• 26.1. South America Biosimilar Hormones Market Overview
• 26.2. South America Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biosimilar Hormones Market

• 27.1. Brazil Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biosimilar Hormones Market

• 28.1. Middle East Biosimilar Hormones Market Overview
• 28.2. Middle East Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biosimilar Hormones Market

• 29.1. Africa Biosimilar Hormones Market Overview
• 29.2. Africa Biosimilar Hormones Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Biosimilar Hormones Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Biosimilar Hormones Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biosimilar Hormones Market Competitive Landscape And Company Profiles

• 30.1. Biosimilar Hormones Market Competitive Landscape
• 30.2. Biosimilar Hormones Market Company Profiles
  • 30.2.1. Teva Pharmaceutical Industries Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Gedeon Richter Plc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Intas Pharmaceuticals Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Biocon Limited
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Mylan
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Biosimilar Hormones Market Competitive Benchmarking

32. Global Biosimilar Hormones Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Biosimilar Hormones Market

34. Biosimilar Hormones Market Future Outlook and Potential Analysis

• 34.1 Biosimilar Hormones Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Biosimilar Hormones Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Biosimilar Hormones Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer